oct-7-enoic acid

We are oct-7-enoic acid CAS:18719-24-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  oct-7-enoic acid
CAS.NO:18719-24-9
Synonyms:
7-octenoic acid
7-octenoic cid
Oct-7-ensaeure
hex-5-enyl-1-acetate
 
Molecular Formula:C8H14O2
Molecular Weight:142.19600
 
Physical and Chemical Properties:
Density:0.946g/cm3
Boiling point:242.1ºC at 760 mmHg
Melting point:14ºC
Flash point:139.4ºC
Index of Refraction:1.45
 
Specification:
Appearance:Light yellow or colorless transparent liquid
Purity:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a dry, inert atmosphere, keep container sealed and store in a cool, dry place
Application:Pharmaceutical intermediate

oct-7-enoic acid


Related News: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.Glycyl-L-Leucine As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.2,3,4,5,6-pentafluorobenzonitrilo CAS:773-82-0 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.N-methylpentan-1-amine CAS:25419-06-1 What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
Retinyl acetate View Details
D-Glutamine View Details
2-Trifluoromethyl-5-Nitrobenzonitrile View Details
2-(chloromethyl)pyridine hydrochloride manufacturer D-histidine manufacturer 2-Phenylethanethiol manufacturer Acetyl Hexapeptide-39 manufacturer 5-Amino-2,3-dichloropyridine manufacturer